On the contrary, in some cancers, such as liver and kidney cancer, tumor cells expressing key enzymes of gluconeogenesis, including PCK1, FBP, and G6P, can promote the whole gluconeogenesis pathway to produce glucose, which, in turn, inhibits the glycolytic pathway. This evidence concerns the gene PCK1 and neoplasm.